查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1830973

體外二氧化碳去除裝置市場

Extracorporeal CO2 Removal Devices Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格
簡介目錄

體外二氧化碳去除裝置市場預計將從 2024 年的 1.125 億美元擴大到 2031 年的 1.8436 億美元，預計 2025 年至 2031 年的複合年成長率為 6.4%。

市場洞察與分析師觀點：慢性阻塞性肺病 (COPD) 盛行率的上升和老齡人口的增加推動了體外二氧化碳去除裝置市場的成長。然而，有關體外二氧化碳去除裝置的嚴格監管對市場成長構成了挑戰。

體外二氧化碳去除裝置因其安全性、有效性和可行性而獲得認可。在臨床應用中，建議用於呼吸支持，以幫助控制慢性阻塞性肺病 (COPD) 和急性呼吸窘迫症候群 (AHRS) 的惡化。眾多製造商正致力於研發技術先進且創新的體外二氧化碳去除裝置，以提升其市場佔有率。此外，越來越多易患慢性阻塞性肺病 (COPD) 的老年患者正在使用體外二氧化碳去除裝置來提高其存活率。因此，肺阻塞性疾病發生率的上升是促進體外二氧化碳去除裝置市場規模擴張的重要因素。然而，使用這些裝置也存在感染、低氧血症或因血流受限而導致的血栓形成等風險，這些風險可能導致嚴重的健康問題，並對市場成長構成長期挑戰。

成長動力：慢性阻塞性肺病發病率上升推動體外二氧化碳去除裝置市場發展2019 年疾病負擔研究報告稱，全球有 2.123 億例 COPD 病例和 330 萬例 COPD 相關死亡病例。空氣污染加劇是導致 COPD 等呼吸系統疾病的重要因素。此外，經濟合作暨發展組織 (OECD) 預測，到 2050 年全球溫室氣體排放量將增加約 50%，二氧化碳排放量將增加 70%。據估計，到 2050 年，大氣中溫室氣體濃度可能達到 685 ppm 二氧化碳當量，可能導致平均氣溫比工業化前水平上升 3 至 6°C。

2021 年 1 月，發表在《PLoS ONE》雜誌上的一項研究表明，法國約有 260 萬人患有 COPD，預計到 2025 年這一數字將增至 280 萬人。根據美國國家健康科學 2022 年的資料，2020-21 年期間，英格蘭約有 117 萬人被診斷出患有 COPD，佔總人口的 1.9%。世界衛生組織將 COPD 確定為全球第三大死因，2022 年造成約 320 萬人死亡。此外，美國肺臟協會報告稱，美國每年有超過 1,100 萬人被診斷出患有 COPD。因此，人群中 COPD 的巨大負擔推動了對體外二氧化碳去除裝置的需求，以增強血液流動並促進有效的氣體交換，從而推動體外二氧化碳去除裝置市場的成長。

策略性洞察報告細分和範圍：「體外二氧化碳去除裝置市場分析」是透過檢查以下細分進行的：產品、應用和最終用戶。

細分分析：根據應用，體外二氧化碳移除裝置市場分為急性呼吸窘迫症候群 (ARDS)、慢性阻塞性肺病 (CBP) 和其他疾病。慢性阻塞性肺病 (CBP) 領域在 2022 年佔據了最大的市場。預計在預測期內，急性呼吸窘迫症候群 (ARDS) 領域的複合年成長率最高，為 7.7%。人們對 ARDS 及其早期發現的認知不斷提高，導致患者診斷和治療數量增加，從而導致對用於 ARDS 管理的體外二氧化碳去除裝置的需求增加。因此，醫療保健提供者越來越有信心將體外二氧化碳去除裝置整合到他們的 ARDS 治療方案中。

體外二氧化碳移除裝置有助於降低呼吸頻率和潮氣量，從而延長呼氣時間，使其更符合呼吸系統的高呼氣時間常數。英國肺臟協會估計，英國約有120萬人被診斷出患有慢性阻塞性肺病 (COPD)。因此，COPD盛行率的上升預計將加速全球體外二氧化碳去除裝置市場的發展。

依產品分類，體外二氧化碳去除裝置市場分為體外二氧化碳去除裝置和耗材。體外二氧化碳去除裝置細分市場在2022年佔據了更大的市場佔有率，而耗材細分市場預計在預測期內將實現更高的複合年成長率，達到7.6%。由於技術簡化，體外二氧化碳去除裝置所需的人員和物流更少，從而提高了患者的偏好。這使得體外二氧化碳去除裝置細分市場得以維持其市場地位。

體外二氧化碳移除過程需要為每位患者提供一套全新的耗材，因此各種COPD和ARDS相關手術對耗材的需求很高。因此，預計體外二氧化碳去除裝置耗材市場在預測期內將持續成長。

按最終用戶分類，市場可細分為醫院和診所、門診手術中心和其他。 2022年，醫院和診所佔據了體外循環二氧化碳去除設備市場的最大佔有率，預計在預測期內將實現7.4%的最高複合年成長率。醫院，尤其是配備專門加護病房 (ICU) 和呼吸科的醫院，擁有救治重症患者的設備。此外，醫院通常擁有由多學科醫療專業人員組成的團隊，包括肺科醫生、重症監護醫生、呼吸治療師和灌注師，他們通力合作，共同治療有複雜呼吸需求的患者。這些專業知識對於安全有效地使用體外循環二氧化碳去除設備至關重要。

技術進步推動體外二氧化碳去除裝置市場發展小型體外二氧化碳去除裝置侵入性較小，可為患者提供更高的舒適度。它們通常需要更小的血管通路，從而降低了併發症的風險。由於患者不再受限於大型、無法移動的裝置，他們可以享受更高的活動性和舒適度，從而提高整體治療品質。膜技術的進步顯著提高了體外二氧化碳去除裝置的有效性和效率，使其能夠選擇性地擴散二氧化碳，同時保留紅血球和蛋白質等重要血液成分。這種選擇性降低了溶血和其他血液相關併發症的風險。

隨著老年人口健康狀況的下降，維持生活品質的需求日益成長，體外二氧化碳去除裝置對於提供微創、更溫和的呼吸支持至關重要。體外二氧化碳去除 (ECCO2R) 的技術創新催生了更方便用戶使用且便攜的設備。隨著 ECCO2R 的益處日益得到認可，它正被納入老年人的治療計劃中。因此，持續的技術進步可能會在未來幾年為體外二氧化碳去除裝置市場帶來新的趨勢。

區域分析：體外二氧化碳去除裝置市場報告的範圍包括北美、歐洲、亞太、南美和中美以及中東和非洲。

2022年，北美佔據了體外二氧化碳去除設備市場的最大佔有率。該地區的成長得益於醫療基礎設施的增強和體外二氧化碳去除設備的高普及率，尤其是在美國和加拿大新冠疫情期間。新技術的早期應用以及ARDS和COPD患者群體的龐大規模預計將進一步加速該地區的市場成長。此外，慢性呼吸系統疾病發生率的上升以及對安全、快速、微創呼吸器的偏好，預計也將在預測期內推動體外二氧化碳去除設備市場的成長。

預計歐洲將佔據全球體外二氧化碳去除設備市場的第二大佔有率，這得益於該地區醫療設備需求的不斷成長以及呼吸衰竭等慢性疾病的發病率不斷上升。此外，優惠的報銷政策、政府對長期醫療保健的投入增加以及醫療保健研究基礎設施的增強，也有助於提高體外二氧化碳去除設備的利用率。

預計亞太地區體外二氧化碳去除裝置市場在預測期內將達到7.3%的最快成長率。這一成長得益於龐大的患者群體、對急性呼吸衰竭認知的提高以及印度和日本等發展中國家政府醫療保健支出的增加。此外，跨國公司正在尋求在中國等發展中國家投資，從而推動該地區的市場成長。

體外二氧化碳去除裝置市場報告範圍：產業發展與未來機會：體外二氧化碳去除裝置市場的預測可以幫助利害關係人規劃其成長策略。以下是一些市場領導企業的策略發展：

2022年10月，ALung Technologies評估了Hemolung呼吸輔助系統（RAS）低流量體外二氧化碳去除（ECCO2R）的安全性和有效性，該系統作為有創機械通氣的替代或輔助手段，適用於因慢性阻塞性肺病（COPD）急性加重而需要呼吸支持的患者。 2022年3月，美國呼吸健康技術公司Respira Labs推出了Sylvee，這是一款由人工智慧驅動的穿戴式肺監測器，利用聲學共振來評估肺功能並檢測肺容量波動。本設備可輔助檢測和治療慢性阻塞性肺病、氣喘和新冠肺炎 (COVID-19)。 2021 年 5 月，ALung Technologies, Inc. 的下一代 Hemolung RAS 體外二氧化碳去除系統獲得 FDA 批准，旨在為急性呼吸衰竭患者提供呼吸支持。 2020 年 5 月，ALung Technologies, Inc. 宣布下一代人工肺 Hemolung RAS 的商業化開發。競爭格局與重點公司：體外二氧化碳去除設備市場報告中介紹的重點公司包括 Getinge、ALung Technologies, Inc.、Estor、NovaLung GmbH、Hemodec、Baxter Healthcare、Eurosets、LivaNova、Medtronic 和 Xenios AG。這些公司專注於開發新技術、改進現有產品並擴大其地理覆蓋範圍，以滿足日益成長的全球消費者需求。

目錄

第1章：簡介

第2章：執行摘要

  • 關鍵見解
  • 市場吸引力分析

第3章：研究方法

第4章：體外二氧化碳去除裝置市場格局

  • 概述
  • PEST分析
  • 生態系分析
    • 價值鏈中的供應商列表

第5章：體外二氧化碳去除裝置市場－關鍵市場動態

  • 關鍵市場促進因素
  • 主要市場限制因素
  • 關鍵市場機會
  • 未來趨勢
  • 促進因素和限制因素的影響分析

第6章：體外二氧化碳去除裝置市場－全球市場分析

  • 體外二氧化碳去除裝置－全球市場概覽
  • 體外二氧化碳去除裝置－全球市場及2030年預測

第7章：體外二氧化碳去除裝置市場-收入分析-依產品，2020-2030

  • 概述
  • 體外二氧化碳裝置
  • 耗材

第 8 章：體外二氧化碳移除裝置市場 - 收入分析 - 按應用，2020-2030 年

  • 概述
  • 慢性阻塞性肺臟疾病
  • 急性呼吸窘迫症候群
  • 其他

第9章：體外二氧化碳移除裝置市場-收入分析-依最終用戶，2020-2030

  • 概述
  • 醫院和診所
  • 門診手術中心
  • 其他

第 10 章：體外二氧化碳移除裝置市場 - 收入分析，2020-2030 年 - 地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
    • 歐洲其他地區
  • 亞太
    • 澳洲
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地區

第 11 章：產業格局

  • 併購
  • 協議、合作、合資企業
  • 新產品發布
  • 擴張和其他策略發展

第 12 章：競爭格局

  • 關鍵參與者的熱圖分析
  • 公司定位與集中度

第 13 章：體外二氧化碳移除裝置市場 - 主要公司簡介

  • Getinge AB
  • ALung Technologies, Inc.
  • Xenios AG
  • Estor SpA
  • Medtronic
  • Hemodec
  • NovaLung GmbH
  • Baxter Healthcare
  • Eurosets
  • LivaNova

第 14 章：附錄

簡介目錄
Product Code: TIPMD00002259

The extracorporeal CO2 removal devices market is anticipated to expand from US$ 112.5 million in 2024 to US$ 184.36 million by 2031, with a projected CAGR of 6.4% from 2025 to 2031.

Market Insights and Analyst Perspective:The growth of the extracorporeal CO2 removal devices market is driven by the rising prevalence of chronic obstructive pulmonary diseases (COPD) and an increasing elderly population. However, stringent regulations concerning extracorporeal CO2 removal devices pose challenges to market growth.

Extracorporeal CO2 removal devices are recognized for their safety, effectiveness, and feasibility. Their application in ventilatory support is recommended in clinical scenarios where they can help manage exacerbations of COPD and acute respiratory distress syndrome. Numerous manufacturers are concentrating on creating technologically advanced and innovative extracorporeal CO2 removal devices to enhance their market presence. Additionally, a growing number of elderly patients susceptible to COPD are being connected to extracorporeal CO2 removal devices to boost their survival rates. Consequently, the rising incidence of pulmonary obstructive diseases is a significant factor contributing to the expansion of the extracorporeal CO2 removal devices market size. Conversely, the use of these devices carries risks such as infection, hypoxemia, or thrombosis due to restricted blood flow, which can lead to severe health issues and present a long-term challenge to market growth.

Growth Drivers:Rising Incidence of Chronic Obstructive Pulmonary Diseases Fuels Extracorporeal CO2 Removal Devices Market

The Burden of Disease Study in 2019 reported 212.3 million cases of COPD and 3.3 million COPD-related deaths worldwide. A significant contributor to respiratory diseases like COPD is the increasing air pollution. Furthermore, the Organization for Economic Co-operation and Development (OECD) predicts that global greenhouse gas emissions will rise by approximately 50% by 2050, with CO2 emissions increasing by 70%. It is also estimated that atmospheric concentrations of greenhouse gases could reach 685 parts per million (ppm) CO2 equivalent by 2050, potentially causing average temperatures to rise by 3 to 6°C above pre-industrial levels.

In January 2021, a study published in the journal PLoS ONE indicated that around 2.6 million individuals in France were affected by COPD, with projections suggesting this number will increase to 2.8 million by 2025. According to 2022 data from National Health Science, approximately 1.17 million people were diagnosed with COPD in England during 2020-21, accounting for 1.9% of the total population. The WHO identifies COPD as the third leading cause of death globally, resulting in about 3.2 million deaths in 2022. Additionally, the American Lung Association reports that over 11 million people in the US are diagnosed with COPD annually. Thus, the substantial burden of COPD within the population drives the demand for extracorporeal CO2 removal devices to enhance blood flow and facilitate efficient gas exchange, thereby propelling the growth of the extracorporeal CO2 removal devices market.

Strategic Insights

Report Segmentation and Scope:The "extracorporeal CO2 removal devices market analysis" has been conducted by examining the following segments: product, application, and end user.

Segmental Analysis:In terms of application, the extracorporeal CO2 removal devices market is divided into acute respiratory distress syndrome, chronic obstructive pulmonary disease, and others. The chronic obstructive pulmonary disease segment accounted for the largest market share in 2022. The acute respiratory distress syndrome segment is expected to exhibit the highest CAGR of 7.7% during the forecast period. Growing awareness of ARDS and its early detection has led to an increase in patient diagnoses and treatments, resulting in heightened demand for extracorporeal CO2 removal devices designed for ARDS management. Consequently, healthcare providers are increasingly confident in integrating extracorporeal CO2 removal devices into their ARDS treatment protocols.

Extracorporeal CO2 removal devices facilitate a reduction in respiratory rate and tidal volume, leading to an extended expiratory time that aligns better with the respiratory system's high expiratory time constant. The British Lung Association estimates that around 1.2 million individuals in the UK are living with diagnosed COPD. Therefore, the rising prevalence of COPD is expected to accelerate the global extracorporeal CO2 removal devices market.

By product, the extracorporeal CO2 removal devices market is categorized into extracorporeal CO2 devices and consumables. The extracorporeal CO2 devices segment held a larger market share in 2022, while the consumables segment is projected to achieve a higher CAGR of 7.6% during the forecast period. Due to technical simplifications, extracorporeal CO2 removal devices require fewer personnel and logistics, enhancing patient preference. This has allowed the extracorporeal CO2 removal devices segment to maintain its market position.

The process of extracorporeal CO2 removal necessitates a fresh set of consumables for each patient, resulting in a high demand for consumables in various COPD and ARDS-related procedures. Thus, the market for the consumables segment of extracorporeal CO2 removal devices is expected to continue its growth during the forecast period.

By end user, the market is segmented into hospitals and clinics, ambulatory surgical centers, and others. The hospitals and clinics segment captured the largest share of the extracorporeal CO2 removal devices market in 2022 and is expected to register the highest CAGR of 7.4% during the forecast period. Hospitals, particularly those with specialized intensive care units (ICUs) and respiratory facilities, are equipped to care for the most critically ill patients. Moreover, hospitals typically have multidisciplinary teams of healthcare professionals, including pulmonologists, critical care physicians, respiratory therapists, and perfusionists, who collaborate to treat patients with complex respiratory needs. This expertise is crucial for the safe and effective use of ECCO2R devices.

Technological Advancements to Propel Extracorporeal CO2 Removal Devices Market

Smaller extracorporeal CO2 removal devices are less invasive and provide greater comfort for patients. They often require smaller vascular access, which reduces the risk of complications. As patients are not confined to large, immobile devices, they can enjoy increased mobility and comfort, enhancing the overall quality of treatment. Advances in membrane technology have significantly improved the effectiveness and efficiency of extracorporeal CO2 removal devices, allowing selective diffusion of CO2 while preserving essential blood components such as red blood cells and proteins. This selectivity reduces the risk of hemolysis and other blood-related complications.

With the growing need to maintain quality of life in the aging population due to their declining health conditions, extracorporeal CO2 removal devices are vital in providing less invasive and gentler respiratory support. Technological innovations in extracorporeal CO2 removal (ECCO2R) have led to the creation of more user-friendly and portable devices. As the benefits of ECCO2R become increasingly recognized, it is being integrated into treatment plans for older adults. Therefore, ongoing technological advancements are likely to introduce new trends in the extracorporeal CO2 removal devices market in the coming years.

Regional Analysis:The scope of the extracorporeal CO2 removal devices market report includes North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

In 2022, North America held the largest share of the extracorporeal CO2 removal devices market. The growth in this region is attributed to enhanced healthcare infrastructure and a high adoption rate of extracorporeal CO2 removal devices, particularly during the COVID-19 pandemic in the US and Canada. The early adoption of new technologies and a large patient population for ARDS and COPD are expected to further accelerate market growth in the region. The rising incidence of chronic respiratory diseases and a preference for safe, rapid, minimally invasive ventilators are also anticipated to boost the growth of the extracorporeal CO2 removal devices market during the forecast period.

Europe is expected to hold the second-largest share of the global extracorporeal CO2 removal devices market, driven by increasing demand for healthcare devices and a rising prevalence of chronic diseases such as respiratory failure in the region. Additionally, favorable reimbursement policies, increased government investments in long-term healthcare, and enhanced healthcare research infrastructures are contributing to higher utilization rates of extracorporeal CO2 removal devices.

The extracorporeal CO2 removal devices market in the Asia Pacific region is projected to experience the fastest growth rate of 7.3% during the forecast period. This growth is fueled by a large patient population, heightened awareness of acute respiratory failure, and increased government healthcare spending in developing countries like India and Japan. Furthermore, multinational companies are looking to invest in developing countries such as China, thereby promoting market growth in the region.

Extracorporeal CO2 Removal Devices Market Report Scope

Industry Developments and Future Opportunities:The forecast for the extracorporeal CO2 removal devices market can assist stakeholders in planning their growth strategies. Below are some strategic developments by leading players in the market:

In October 2022, ALung Technologies assessed the safety and effectiveness of the hemolung respiratory assist system (RAS) for low-flow extracorporeal CO2 removal (ECCO2R) as an alternative or adjunct to invasive mechanical ventilation for patients needing respiratory support due to acute exacerbations of chronic obstructive pulmonary disease (COPD).

In March 2022, Respira Labs, a US-based respiratory health technology firm, launched Sylvee, an AI-powered wearable lung monitor that utilizes acoustic resonance to evaluate lung function and detect fluctuations in lung volume. This device can aid in the detection and treatment of chronic obstructive pulmonary disease, asthma, and COVID-19.

In May 2021, ALung Technologies, Inc. received FDA clearance for its next-generation Hemolung RAS extracorporeal CO2 removal system, designed to provide respiratory support to patients experiencing acute respiratory failure.

In May 2020, ALung Technologies, Inc. announced the commercial development of the next-generation artificial lung known as the hemolung RAS.

Competitive Landscape and Key Companies:Key companies profiled in the extracorporeal CO2 removal devices market report include Getinge, ALung Technologies, Inc., Estor, NovaLung GmbH, Hemodec, Baxter Healthcare, Eurosets, LivaNova, Medtronic, and Xenios AG. These companies are focused on developing new technologies, enhancing existing products, and expanding their geographic reach to meet the growing global consumer demand.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Extracorporeal CO2 Removal Devices Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Extracorporeal CO2 Removal Devices Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Extracorporeal CO2 Removal Devices Market - Global Market Analysis

  • 6.1 Extracorporeal CO2 Removal Devices - Global Market Overview
  • 6.2 Extracorporeal CO2 Removal Devices - Global Market and Forecast to 2030

7. Extracorporeal CO2 Removal Devices Market - Revenue Analysis (USD Million) - By Product, 2020-2030

  • 7.1 Overview
  • 7.2 Extracorporeal CO2 Devices
  • 7.3 Consumables

8. Extracorporeal CO2 Removal Devices Market - Revenue Analysis (USD Million) - By Application, 2020-2030

  • 8.1 Overview
  • 8.2 Chronic Obstructive Pulmonary Disease
  • 8.3 Acute Respiratory Distress Syndrome
  • 8.4 Others

9. Extracorporeal CO2 Removal Devices Market - Revenue Analysis (USD Million) - By End User, 2020-2030

  • 9.1 Overview
  • 9.2 Hospitals and Clinics
  • 9.3 Ambulatory Surgical Centers
  • 9.4 Others

10. Extracorporeal CO2 Removal Devices Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

  • 10.1 North America
    • 10.1.1 North America Extracorporeal CO2 Removal Devices Market Overview
    • 10.1.2 North America Extracorporeal CO2 Removal Devices Market Revenue and Forecasts to 2030
    • 10.1.3 North America Extracorporeal CO2 Removal Devices Market Revenue and Forecasts and Analysis - By Product
    • 10.1.4 North America Extracorporeal CO2 Removal Devices Market Revenue and Forecasts and Analysis - By Application
    • 10.1.5 North America Extracorporeal CO2 Removal Devices Market Revenue and Forecasts and Analysis - By End User
    • 10.1.6 North America Extracorporeal CO2 Removal Devices Market Revenue and Forecasts and Analysis - By Countries
      • 10.1.6.1 United States Extracorporeal CO2 Removal Devices Market
        • 10.1.6.1.1 United States Extracorporeal CO2 Removal Devices Market, by Product
        • 10.1.6.1.2 United States Extracorporeal CO2 Removal Devices Market, by Application
        • 10.1.6.1.3 United States Extracorporeal CO2 Removal Devices Market, by End User
      • 10.1.6.2 Canada Extracorporeal CO2 Removal Devices Market
        • 10.1.6.2.1 Canada Extracorporeal CO2 Removal Devices Market, by Product
        • 10.1.6.2.2 Canada Extracorporeal CO2 Removal Devices Market, by Application
        • 10.1.6.2.3 Canada Extracorporeal CO2 Removal Devices Market, by End User
      • 10.1.6.3 Mexico Extracorporeal CO2 Removal Devices Market
        • 10.1.6.3.1 Mexico Extracorporeal CO2 Removal Devices Market, by Product
        • 10.1.6.3.2 Mexico Extracorporeal CO2 Removal Devices Market, by Application
        • 10.1.6.3.3 Mexico Extracorporeal CO2 Removal Devices Market, by End User
  • 10.2 Europe
    • 10.2.1 Germany
    • 10.2.2 France
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Rest of Europe
  • 10.3 Asia-Pacific
    • 10.3.1 Australia
    • 10.3.2 China
    • 10.3.3 India
    • 10.3.4 Japan
    • 10.3.5 South Korea
    • 10.3.6 Rest of Asia-Pacific
  • 10.4 Middle East and Africa
    • 10.4.1 South Africa
    • 10.4.2 Saudi Arabia
    • 10.4.3 U.A.E
    • 10.4.4 Rest of Middle East and Africa
  • 10.5 South and Central America
    • 10.5.1 Brazil
    • 10.5.2 Argentina
    • 10.5.3 Rest of South and Central America

11. Industry Landscape

  • 11.1 Mergers and Acquisitions
  • 11.2 Agreements, Collaborations, Joint Ventures
  • 11.3 New Product Launches
  • 11.4 Expansions and Other Strategic Developments

12. Competitive Landscape

  • 12.1 Heat Map Analysis by Key Players
  • 12.2 Company Positioning and Concentration

13. Extracorporeal CO2 Removal Devices Market - Key Company Profiles

  • 13.1 Getinge AB
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 ALung Technologies, Inc.
  • 13.3 Xenios AG
  • 13.4 Estor SpA
  • 13.5 Medtronic
  • 13.6 Hemodec
  • 13.7 NovaLung GmbH
  • 13.8 Baxter Healthcare
  • 13.9 Eurosets
  • 13.10 LivaNova

14. Appendix

  • 14.1 Glossary
  • 14.2 About The Insight Partners
  • 14.3 Market Intelligence Cloud